天坛生物获万联证券买入评级，浆站获批能力强，研发布局夯实长期竞争力

金融界06-21

6月21日，天坛生物获万联证券买入评级，近一个月天坛生物获得2份研报关注。研报认为，天坛生物依托央企股东背景，具备较强的浆站获批能力，2021年以来新设浆站资源储备丰厚，未来有望逐步进入收益兑现期。长期看，血制品属于高壁垒资源型赛道，公司有望凭借内生增长和外延拓展双实力实现稳健增长。研报预计，公司多项血制品经营指标行业领先。根据2023年年报，公司拥有血制品品种数量15个，单采血浆站分布于全国16...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2445060382?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-21 10:57","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2445060382","market":"sh","top_or_hot":-1,"title":"天坛生物获万联证券买入评级，浆站获批能力强，研发布局夯实长期竞争力","media":"金融界","content":"<div>\n<p>6月21日，天坛生物获万联证券买入评级，近一个月天坛生物获得2份研报关注。研报认为，天坛生物依托央企股东背景，具备较强的浆站获批能力，2021年以来新设浆站资源储备丰厚，未来有望逐步进入收益兑现期。长期看，血制品属于高壁垒资源型赛道，公司有望凭借内生增长和外延拓展双实力实现稳健增长。研报预计，公司多项血制品经营指标行业领先。根据2023年年报，公司拥有血制品品种数量15个，单采血浆站分布于全国16...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062111071595c7c490&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>天坛生物获万联证券买入评级，浆站获批能力强，研发布局夯实长期竞争力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n天坛生物获万联证券买入评级，浆站获批能力强，研发布局夯实长期竞争力\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-21 10:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062111071595c7c490&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>6月21日，天坛生物获万联证券买入评级，近一个月天坛生物获得2份研报关注。研报认为，天坛生物依托央企股东背景，具备较强的浆站获批能力，2021年以来新设浆站资源储备丰厚，未来有望逐步进入收益兑现期。长期看，血制品属于高壁垒资源型赛道，公司有望凭借内生增长和外延拓展双实力实现稳健增长。研报预计，公司多项血制品经营指标行业领先。根据2023年年报，公司拥有血制品品种数量15个，单采血浆站分布于全国16...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062111071595c7c490&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161027","symbol_name":"证券","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062111071595c7c490&s=b","article_id":"2445060382","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062111071595c7c490&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2445060382","pubTimestamp":1718938642,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"6月21日，天坛生物获万联证券买入评级，近一个月天坛生物获得2份研报关注。研报认为，天坛生物依托央企股东背景，具备较强的浆站获批能力，2021年以来新设浆站资源储备丰厚，未来有望逐步进入收益兑现期。研报认为，天坛生物在重组人凝血因子类和人免疫球蛋白类产品的研发领域保持国内同行业的领先地位，新产品有望优化公司收入结构，保持公司在行业内的长期竞争优势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"161027":"证券","600161":"天坛生物"},"translate_title":"Tiantan Biology received a buy rating from Wanlian Securities, the pulp station has a strong ability to be approved, and the R&D layout has consolidated long-term competitiveness","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"600161":1},"content_text":"6月21日，天坛生物获万联证券买入评级，近一个月天坛生物获得2份研报关注。研报认为，天坛生物依托央企股东背景，具备较强的浆站获批能力，2021年以来新设浆站资源储备丰厚，未来有望逐步进入收益兑现期。长期看，血制品属于高壁垒资源型赛道，公司有望凭借内生增长和外延拓展双实力实现稳健增长。研报预计，公司多项血制品经营指标行业领先。根据2023年年报，公司拥有血制品品种数量15个，单采血浆站分布于全国16个省/自治区，总数达102家，其中在营数量达80家。2021年以来，公司浆站数量增长较快。未来随着公司浆站步入成熟阶段，以及研发新品种，高毛利品种占比提升，公司采浆效率和血浆综合利用率有较大成长空间，推动吨浆盈利水平提高。研报认为，天坛生物在重组人凝血因子类和人免疫球蛋白类产品的研发领域保持国内同行业的领先地位，新产品有望优化公司收入结构，保持公司在行业内的长期竞争优势。研报预计公司2024/2025/2026年归母净利润分别为13.58亿元/16.39亿元/19.92亿元。风险提示：原材料供应不足的风险，采浆成本上升的风险，产品研发进展不达预期风险。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2445060382"}